Saturday 17 October 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.
2.70
0.04
−1.46%
Follow ARTL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(436.14%) | (1,625.11%) | (367.70%) | (705.71%) | |
| (219.08%) | (343.49%) | (167.97%) | (234.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (865.85%) | |
Return on Tangible Assets |
411.84% | 384.56% | (293.16%) | (434.53%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(280.96) | (223.62) | (98.83) | (41.93) | |
Free Cash Flow |
(8.18) | (8.52) | (8.11) | (12.63) | |
| Other line items | |||||
Cash ROIC |
(752.16%) | 1,267.86% | (47.88%) | (137.39%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(65.77) | (40.44) | (29.21) | (33.04) | |
Operating CF/Net income |
0.65 | 0.66 | 0.60 | 1.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(280.96) | (223.62) | (98.83) | (41.93) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 28 Sep 2026